Where Are They Now? Insights from Anti-Obesity Medication Users Past and Present

The adoption of anti-obesity medications (AOMs), such as GLP-1 receptor agonists, continues to accelerate globally, with spending projected to reach nearly $200 billion by 2029 (according to the IQVIA Institute for Human Data Science).

ADM's latest proprietary consumer survey examines the evolving AOM landscape, uncovering how both current users and those transitioning off these medications are reshaping expectations for food, beverage and dietary supplement solutions.

The findings detail two distinct consumer journeys. Current GLP-1 medication users overwhelmingly report satisfaction with their progress. They also have a strong willingness to invest in solutions that can support them while using AOMs, with a specific focus on portion control and nutritional value.

ADM insights also revealed the drivers for consumers stopping GLP-1 medication use, including reaching health goals, side effects or cost. However, many struggle with weight regain and the return of "food noise," prompting interest in solutions targeting these areas.

Across both groups, the demand for enjoyable and convenient functional products tailored for specific needs is clear. For food, beverage and dietary supplement manufacturers, this research highlights powerful opportunities, from leveraging innovative biotics, fiber and protein ingredients to spotlighting specific wellness benefits like digestive and metabolic support, hydration, satiety and more.

Explore the full report here.